News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,672 Results
Type
Article (13839)
Company Profile (101)
Press Release (252732)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88080)
Career Advice (465)
Deals (15348)
Drug Delivery (67)
Drug Development (36608)
Employer Resources (49)
FDA (6302)
Job Trends (6205)
News (150279)
Policy (14050)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (38)
Alliances (23247)
ALS (39)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (46)
Approvals (6341)
Artificial intelligence (115)
Autoimmune disease (9)
Automation (5)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (23)
Brain cancer (16)
Breast cancer (84)
Cancer (666)
Cardiovascular disease (74)
Career advice (409)
Career pathing (12)
CAR-T (24)
Cell therapy (92)
Cervical cancer (4)
Clinical research (30995)
Collaboration (372)
Compensation (168)
Complete response letters (17)
COVID-19 (760)
CRISPR (23)
C-suite (135)
Cystic fibrosis (39)
Data (720)
Denatured (15)
Depression (10)
Diabetes (84)
Diagnostics (1330)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (62)
Drug pricing (71)
Drug shortages (12)
Duchenne muscular dystrophy (42)
Earnings (32465)
Editorial (14)
Employer branding (4)
Employer resources (43)
Events (37698)
Executive appointments (415)
FDA (6808)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (229)
Gene editing (41)
Generative AI (9)
Gene therapy (106)
GLP-1 (355)
Government (1308)
Grass and pollen (3)
Guidances (74)
Healthcare (3566)
Huntington's disease (4)
IgA nephropathy (13)
Immunology and inflammation (38)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (58)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (50)
Interviews (59)
IPO (5891)
IRA (29)
Job creations (2053)
Job search strategy (373)
Kidney cancer (6)
Labor market (14)
Layoffs (184)
Leadership (4)
Legal (3434)
Liver cancer (19)
Lung cancer (88)
Lymphoma (60)
Machine learning (4)
Management (16)
Manufacturing (177)
MASH (37)
Medical device (1279)
Medtech (1281)
Mergers & acquisitions (9681)
Metabolic disorders (275)
Multiple sclerosis (23)
NASH (14)
Neurodegenerative disease (29)
Neuropsychiatric disorders (9)
Neuroscience (596)
NextGen: Class of 2025 (1586)
Non-profit (596)
Now hiring (8)
Obesity (155)
Opinion (119)
Ovarian cancer (22)
Pain (58)
Pancreatic cancer (17)
Parkinson's disease (48)
Partnered (7)
Patents (131)
Patient recruitment (30)
Peanut (10)
People (29024)
Pharmaceutical (64)
Pharmacy benefit managers (13)
Phase I (8072)
Phase II (13115)
Phase III (11762)
Pipeline (582)
Policy (76)
Postmarket research (1401)
Preclinical (3239)
Press Release (25)
Prostate cancer (49)
Psychedelics (8)
Radiopharmaceuticals (121)
Rare diseases (176)
Real estate (2637)
Recruiting (17)
Regulatory (10165)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (3)
RSV (8)
Schizophrenia (39)
Series A (40)
Series B (16)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1630)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (39)
The Weekly (30)
Vaccines (161)
Venture capitalists (14)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (82)
Last 7 days (322)
Last 30 days (1202)
Last 365 days (11607)
2025 (4529)
2024 (12502)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13130)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (59)
Arkansas (3)
Asia (20185)
Australia (2619)
California (1908)
Canada (975)
China (258)
Colorado (74)
Connecticut (74)
Delaware (65)
Europe (39611)
Florida (368)
Georgia (42)
Idaho (9)
Illinois (213)
India (16)
Indiana (142)
Iowa (1)
Japan (105)
Kansas (61)
Kentucky (13)
Louisiana (2)
Maine (2)
Maryland (277)
Massachusetts (1645)
Michigan (32)
Minnesota (102)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (830)
New Mexico (7)
New York (559)
North Carolina (414)
North Dakota (2)
Northern California (791)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (480)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (805)
Tennessee (36)
Texas (255)
United States (7909)
Utah (36)
Virginia (86)
Washington D.C. (32)
Washington State (129)
Wisconsin (21)
266,672 Results for "recce pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
April 23, 2025
·
5 min read
Press Releases
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
·
3 min read
Press Releases
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
November 27, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
April 11, 2025
·
8 min read
Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.
May 8, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
February 19, 2025
·
5 min read
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.
May 13, 2024
·
4 min read
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
Recce Pharmaceuticals Ltd today announced its primary anti-infective candidate, RECCE ® 327 (R327), has been added to the World Health Organization’s (WHO) list of Antibacterial Agents in Clinical Development and Preclinical Development.
June 20, 2024
·
3 min read
Press Releases
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
January 23, 2025
·
5 min read
Drug Development
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
Recce Pharmaceuticals Ltd today announced it received Human Research Ethics Committee (HREC) approval to commence a Phase II trial assessing its lead candidate, RECCE® 327 (R327), as a topical, broad-spectrum gel for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
June 25, 2024
·
4 min read
1 of 26,668
Next
